Document is current
Any future updates will be listed below
-
Authors
Huang, Xinran
Liang, Xiaoting
Han, Qian
Shen, Ying
Chen, Jiaqi
Li, Ziqi
Qiu, Jie
Gao, Xiaoyan
Hong, Yimei
Lin, Fang
Li, Weifeng
Li, Xin
Zhang, Yuelin https://orcid.org/0000-0002-0065-1116
-
Funding
Funding for this research was provided by:
Innovative Research Group Project of the National Natural Science Foundation of China (No. 82270253)
Innovative Research Group Project of the National Natural Science Foundation of China (No. 82170073)
Innovative Research Group Project of the National Natural Science Foundation of China (No. 82072225)
Science Fund for Distinguished Young Scholars of Guangdong Province (20022B1515020104)
Science Fund for Distinguished Young Scholars of Guangdong Province (20022A1515012501)
Science Fund for Distinguished Young Scholars of Guangdong Province (KY0120220132)
Key Technologies Research and Development Program (2023YFE0114300)
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 28 October 2024
First Online: 10 November 2024
Declarations
:
: All cell cultures in this study were reviewed and approved by the Ethics Committees of Tongji University (Approved project: mesenchymal stem cell-based therapy for myocardial infarction, Approval No. 2016-050, Date of approval: Sep 18, 2016). Written informed consents were obtained from patients and their families for participation in the study and the use of samples. All animal procedures were performed in accordance with the ARRIVE guidelines and approved by approved by the Committee on the Use of Live Animals in Teaching and Research of Tongji University for Laboratory Animal Medicine (Approved project: The therapeutic effects of growth differentiation factor 15 pretreated mesenchymal Stem Cells on myocardial infarction, Approval No. TJBB04724101, Date of approval: Feb 28, 2024).
: All authors have read and approved the final version of the manuscript.
: The authors declare that they have no competing interests.
